IP Library › Patent Application 17373714
Patent Application
App. No. 17/373,714

NOVEL GLUE FOR EMBOLIZATION OF LYMPHATIC LEAKAGE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/373,714
Abstract

A novel glue for embolization of lymphatic leakage. An optimized lymphatic embolization agent (LEA) as described herein comprises a NAM hydrogel and tantalum at a mixture of at or about 1:3 tantalum to NAM hydrogel, wherein said LEA is radiopaque.

Claims (17)

1 . An optimized lymphatic embolization agent (LEA), comprising a NAM hydrogel and tantalum at a mixture of at or about 1:3 tantalum to NAM hydrogel, wherein said LEA is radiopaque.

2 . The LEA of claim 1 , wherein the NAM hydrogel comprises N 93 Am 7 .

3 . The LEA of claim 2 , wherein the N 93 Am 7 is produced by dissolving NIPAM, Am and 2,2′ azobisisobutryonitrile in tetrahydrofuran, degassing under elevated temperature, and isolating the resultant product, wherein the resultant product comprises N 93 Am 7 .

4 . The LEA of claim 2 , wherein the N 93 Am 7 is synthesized by free radical polymerization.

5 . The LEA of claim 1 , configured for injection into a mammalian subject through a 3 Fr catheter.

6 . The LEA of claim 1 , configured to solidify within 45 seconds at a temperature of 37° C.

7 . The LEA of claim 1 , configured to solidify within 30 seconds at a temperature of 37° C.

8 . The LEA of claim 1 , configured to solidify within 15 seconds at a temperature of 37° C.

9 . The LEA of claim 1 , configured to resist displacement under 800 mmHg of pressure after 60 seconds at 37° C.

10 . The LEA of claim 1 , configured as a lymphatic sealant.

11 . A method of occluding a lymphatic vessel, comprising:

introducing the LEA of claim 1 into a mammalian patient at or near a lymphatic vessel to occlude said vessel.

12 . The method of claim 11 , wherein the step of introducing comprises introducing at or about 3 ml of the LEA so that at or about 1 ml of solid glue forms at or about 37° C.

13 . The method of claim 11 , wherein the solid glue resists migration.

14 . A method of treating lymphatic leakage, comprising introducing the LEA of claim 1 into a mammalian patient at or near a lymphatic vessel to treat the lymphatic leakage.

15 . The method of claim 14 , wherein the step of introducing comprises introducing at or about 3 ml of the LEA so that at or about 1 ml of solid glue forms at or about 37° C.

16 . The method of claim 14 , wherein the solid glue resists migration.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2022
From: KASSAB, GHASSAN S.; DABIRI, ALI
To: 3DT HOLDINGS, LLC
Reel/Frame 058999/0398 →